Finch Therapeutics

📍 Somerville, United States👥 20 employees💰 Last funded Sep 2017
Biotechnology Research🌐 finchtherapeutics.com
Website LinkedIn
Finch Therapeutics has a portfolio of microbiome assets including CP101, a late-stage, investigational, orally administered microbiome candidate with positive clinical data from a Phase 2 randomized, placebo-controlled trial and a Phase 2 open-label trial in recurrent C. difficile infection (CDI). Additionally, Finch has pre-clinical assets that are designed to target ulcerative colitis, Crohn’s disease, and autism spectrum disorder. Finch has a robust intellectual property estate reflecting the Company’s pioneering role in the microbiome therapeutics field, including more than 70 issued U.S. and foreign patents with critical relevance for both donor-derived and donor-independent microbiome therapeutics in a range of potential indications. In January 2023, Finch announced a decision to discontinue its Phase 3 trial of CP101 in recurrent CDI and focus on realizing the value of its intellectual property estate and other assets.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
2
Frequently asked questions
Who invested in Finch Therapeutics?
Finch Therapeutics has 2 investors on record on gritt.io.
When did Finch Therapeutics last raise funding?
The most recent investment in Finch Therapeutics recorded on gritt.io was in September 2017.
What industry is Finch Therapeutics in?
Finch Therapeutics operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is Finch Therapeutics based?
Finch Therapeutics is headquartered in Somerville, United States.